Related Experiment Video
Updated: Jan 27, 2026

Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice
Published on: July 25, 2014
Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR
Jurjen Versluis1, Jan J Cornelissen1
1Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) strongly reduces relapse in patients with acute myeloid leukemia (AML) in first complete remission (CR). Estimated as relative risk, the graft-vs-leukemia effect of alloHSCT is associated with a hazard ratio of approximately 0.35 with endpoint relapse compared with autologous HSCT or postremission chemotherapy in comparative studies. Strikingly, that hazard ratio is similarly operational in favorable and adverse-risk AML. It suggests that only in case of excessive nonrelapse mortality (NRM) alloHSCT should be withheld as postremission treatment. Therefore, the application of alloHSCT in patients with AML in first CR should be personalized and based on both risks and benefits of alloHSCT, which are on the one hand the risk for NRM and on the other hand the risk of relapse. The risk of NRM can be estimated by a dedicated score for patients with AML in first CR, whereas the latest European LeukemiaNET risk classification may be applied for estimating the risk of relapse. In addition, the assessment of measurable residual disease further discriminates patients with a low vs high risk of relapse and may be incorporated in decision making.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) strongly reduces relapse in patients with acute myeloid leukemia (AML) in first complete remission (CR). Estimated as relative risk, the graft-vs-leukemia effect of alloHSCT is associated with a hazard ratio of approximately 0.35 with endpoint relapse compared with autologous HSCT or postremission chemotherapy in comparative studies. Strikingly, that hazard ratio is similarly operational in favorable and adverse-risk AML. It suggests that only in case of excessive nonrelapse mortality (NRM) alloHSCT should be withheld as postremission treatment. Therefore, the application of alloHSCT in patients with AML in first CR should be personalized and based on both risks and benefits of alloHSCT, which are on the one hand the risk for NRM and on the other hand the risk of relapse. The risk of NRM can be estimated by a dedicated score for patients with AML in first CR, whereas the latest European LeukemiaNET risk classification may be applied for estimating the risk of relapse. In addition, the assessment of measurable residual disease further discriminates patients with a low vs high risk of relapse and may be incorporated in decision making.
More Related Videos
Related Concept Videos
Benefits of Self-Esteem
Relative Risk
Personal Identity
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Self-Report Tests of Personality
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

